Holen Sie sich die Stockscreener-App
0.0001
51.40%
-0.111
Schlusskurs vom Vortag:
$0.1111
Offen:
$0.0001
24-Stunden-Volumen:
2,287
Relative Volume:
66.00
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
$-66.00M
KGV:
-0.000172
EPS:
-0.58
Netto-Cashflow:
$-60.55M
1W Leistung:
-51.40%
1M Leistung:
-87.90%
6M Leistung:
-95.00%
1J Leistung:
-97.29%
1-Tages-Spanne:
$0.0001
$0.0001
1-Wochen-Bereich:
$0.0001
$0.0001
52-Wochen-Spanne:
$0.0001
$0.0001
Vaxxinity Inc Stock (VAXX) Company Profile
Vergleichen Sie VAXX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VAXX
Vaxxinity Inc
|
0.0001 | 0 | 0 | -66.00M | -60.55M | -0.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Vaxxinity Inc Stock (VAXX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-09-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-04-27 | Eingeleitet | Evercore ISI | In-line |
Vaxxinity Inc Aktie (VAXX) Neueste Nachrichten
Victory Capital (NASDAQ:VCTR) Hits New 12-Month High at $56.29 - MarketBeat
IPO Roundup: Guardian Pharmacy Services, BKV Corp and more (NYSEARCA:IPO) - Seeking Alpha
Victory Capital Management Inc. Has $496,000 Stock Holdings in Zymeworks Inc. (NYSE:ZYME) - Defense World
Victory Capital Management Inc. Makes New Investment in MediaAlpha, Inc. (NYSE:MAX) - Defense World
Zhengye Biotechnology Holding Limited Plans $7 Million IPO for September 27th (ZYBT) - Defense World
Victory Capital Management Inc. Increases Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Broker tips: Volution, UK supermarkets - ShareCast
Vaxcyte president and CFO sells over $900k in stock - Investing.com
Wave Life Sciences gains as B. Riley issues buy on RNS editing tech - MSN
Waltham biotech joins IPO buzz, plans to list on Nasdaq - The Business Journals
Vaxxinity (OTC:VAXX) Stock Quotes, Forecast and News Summary - Benzinga
Vaxxinity (NASDAQ:VAXX) Stock Price Up 13.2% - Defense World
Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine - GlobeNewswire
Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine - The Bakersfield Californian
Vaxxinity (NASDAQ:VAXX) Trading 11.4% Higher - Defense World
Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market - Fierce Biotech
Vaxxinity (VAXX) Stock Forecast and Price Target 2024 - MarketBeat
Why Is Vaxxinity (VAXX) Stock Up 39% Today? - InvestorPlace
Why Vaxxinity (VAXX) Shares Are Volatile Today - Benzinga
Why Is Vaxxinity (VAXX) Stock Down 58% Today? - InvestorPlace
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock - Yahoo Finance
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting - GlobeNewswire
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates - Yahoo Finance
AD/PD 2024: Vaxxinity reveals Phase I success with Parkinson’s vaccine - Pharmaceutical Technology
Vaxxinity Announces Positive Target Engagement Data from - GlobeNewswire
Private companies in Vaxxinity, Inc. (NASDAQ:VAXX) are its biggest bettors, and their bets paid off as stock gained 22% last week - Simply Wall St
Vaxxinity Faces Nasdaq Delisting Over Share Price - TipRanks
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published - GlobeNewswire
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024 - Yahoo Finance
Vaxxinity is brewing up meds for a spacefaring future - PharmaVoice
Vaxxinity, UF Join Forces Against Neurodegenerative Diseases - Yahoo Finance
Vaxxinity Wants to Bring Accessible Vaccines for Chronic Illness to Market - Cheddar
Vaxxinity, UCF to develop special new vaccines for deep-space astronauts - The Business Journals
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference - GlobeNewswire
Vaxxinity making vaccines to change the world - Labiotech.eu
Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewswire
Private companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap decline - Yahoo Finance
Down -22.18% in 4 Weeks, Here's Why You Should You Buy the Dip in Vaxxinity, Inc. (VAXX) - Yahoo Finance
Fast-Tracked Alzheimer's Vaccine Seems to Work, But Phase 3 Trials Stalled - Being Patient
Vaxxinity publishes positive results in Alzheimer’s trial - Longevity.Technology
Vaxxinity Alzheimer’s treatment shows promising results in early trial - BioPharma-Reporter.com
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease - Yahoo Finance
Vaxxinity Appoints Dr. Peter Powchik as Global Scientific Director - Yahoo Finance
Vaxxinity Appoints Peter Powchik, M.D., to EVP, Global Scientific Director - citybiz
Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients - GlobeNewswire
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease - South Florida Hospital News
Vaxxinity celebrates trial success in early Parkinson's therapy - Clinical Trials Arena
Positive Phase 1 Results: Vaxxinity’s UB-312 Shows Promise in Parkinson’s Disease - Yahoo Finance
Vaxxinity shares update about potential vaccine UB-312 - Parkinson's News Today
VXX-301, a tau vaccine with optimized properties - BioWorld Online
Vaxxinity to Present at World Vaccine Congress, American - GlobeNewswire
Finanzdaten der Vaxxinity Inc-Aktie (VAXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.35%
0.87%
Kapitalisierung:
|
Volumen (24h):